Admission to Trading and First Day of Dealings

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, TO UNITED STATES NEWS WIRE SERVICES OR IN OR INTO, AUSTRALIA, CANADA, JAPAN, THE UNITED STATES OF AMERICA OR SOUTH AFRICA OR ANY JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT.

Bermele Plc

("Bermele" or "the Company")

Admission to Trading and First Day of Dealings

Bermele, a Company formed to acquire a target company (or companies) with realisable or developed commercial technologies in the pharmaceutical and biotechnology sector, is pleased to announce that its entire issued ordinary share capital consisting of 200,000,000 Ordinary Shares of 0.1p each (the "Ordinary Shares") will today be admitted to the standard segment of the Official List of the UKLA and to trading on the Main Market for listed securities of the London Stock Exchange (together "Admission"). Dealings are expected to commence at 8:00 a.m. under the TIDM code "BERM" (ISIN: GB00BJ1F3295).

Copies of the Prospectus in relation to the Admission are available for inspection, subject to applicable securities laws, from the Company's website at www.bermele.com/prospectus. Defined terms in this announcement shall have the same meanings as in the Prospectus.

Highlights

· Bermele has been formed for the purpose of acquiring a business or businesses operating in the pharmaceutical and biotechnology sector ("the Acquisition").

· The Company will look to acquire a target company with products and technology already at a stage of research and development that will add value to the Company.

· There are many categories of serious illness within diabetes, mental health and oncology that can and will benefit from technological advances in diagnosis and treatment such as personalised medicine. It is within these serious ailment categories across the diagnosis, prevention, and disease management areas that the Company will initially look for its acquisition target.

STATISTICS

Enquiries: